Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01526928 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

612

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Non Small Cell Lung Cancer

Interventions

DRUG: Rociletinib
DRUG: Rociletinib
DRUG: Rociletinib
DRUG: Rociletinib
DRUG: Rociletinib
DRUG: Rociletinib

Sponsor

Clovis Oncology, Inc.